Nasdaq:EXEL
EXELIXIS, INC.
A biopharmaceutical innovator commercializing targeted oncology and rare disease therapies with robust cash flow and accelerating profitability.
Key Metrics
Investment Thesis
Bull Case
Exelixis presents a compelling value proposition with a massive cash hoard exceeding $480 million and a proven ability to generate substantial net income growth. The company's proprietary approach to targeting rare genetic mutations offers a clear path to differentiated market access in high-value oncology and rare disease niches. Strong operational leverage is evident as revenue has grown from $1.61 billion in 2022 to $2.32 billion, correlating with a nearly fourfold increase in net income.
Bear Case
Investors should remain cautious regarding the company's heavy reliance on share repurchases totaling $947.5 million, which may limit capital available for further pipeline expansion or R&D. The significant reduction in accounts payable of -$50.2M and negative change in working capital could indicate tightening liquidity conditions or aggressive expense management that masks underlying operational stress. Regulatory uncertainties in the oncology sector pose a persistent threat to the commercialization timeline of any new assets entering late-stage development.
About EXELIXIS, INC.
Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines primarily for oncology and rare diseases. The company leverages its proprietary platform to create therapies that target specific genetic mutations, serving patients with cancer and orphan conditions in the United States and internationally. Recent financials highlight significant growth in revenue and net income driven by successful product launches and strong operational performance.
Analysis
Management Discussion
The company demonstrated exceptional financial health with net profit reaching $782.6 million in 2026, up from $521.3 million the prior year, indicating a rapidly scaling commercial engine. Operating cash flow of $884.3 million strongly exceeds net income, suggesting high quality earnings and efficient working capital management. However, the massive cash outflow from financing activities of -$969.6 million suggests significant share repurchases or strategic investments that warrant close monitoring.
Industry Overview
The global biopharmaceutical industry is currently driven by advancements in precision medicine, where therapies targeting specific genetic mutations are becoming the standard for treating cancer and rare diseases. Competition remains fierce as large pharmaceutical companies expand their oncology portfolios, forcing mid-cap innovators to secure exclusive licensing deals or demonstrate superior clinical data. Regulatory environments continue to evolve, requiring rigorous adherence to safety standards that can delay product launches and increase development costs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue | $1.61B | $1.83B | $2.17B | $2.32B |
| Cost of Revenue | $57.9M | $72.5M | $76.2M | $83.7M |
| Gross Profit | $1.55B | $1.76B | $2.09B | $2.24B |
| Operating Expenses | $1.35B | $1.59B | $1.49B | $1.36B |
| Operating Income | $201.5M | $170.9M | $604.6M | $872.2M |
| R&D | $891.8M | $1.04B | $910.4M | $825.0M |
| G&A | $459.9M | $542.7M | $492.1M | $518.7M |
| Stock-Based Comp | $107.6M | $106.3M | $93.8M | $113.0M |
| D&A | $20.9M | $25.7M | $28.8M | $29.1M |
| Depreciation | $20.9M | $25.7M | — | — |
| Other OpEx | $0 | $0 | $85.3M | $20.5M |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | $33.1M | $86.5M | $77.2M | $69.2M |
| Pre-Tax Income | $201.5M | $170.9M | $604.6M | $872.2M |
| Income Tax | $52.1M | $49.8M | $160.4M | $158.6M |
| Continuing Ops | $149.4M | $121.1M | $444.2M | $713.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $182.3M | $207.8M | $521.3M | $782.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $182.3M | $207.8M | $521.3M | $782.6M |
| Metric | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|
| Current Assets | $1.62B | $1.32B | $1.47B | $1.44B |
| Cash & Equivalents | $501.2M | $263.0M | $217.4M | $482.5M |
| Marketable Securities | $807.3M | $732.3M | $893.9M | $576.6M |
| Inventory | $33.3M | $17.3M | $22.4M | $21.7M |
| Prepaid Expenses | $62.2M | $67.9M | $68.5M | $75.6M |
| Other Current Assets | $214.8M | $237.4M | $265.4M | $286.9M |
| Long-Term Assets | $1.45B | $1.62B | $1.48B | $1.40B |
| PP&E (Net) | $110.6M | $128.7M | $119.4M | $99.0M |
| Goodwill | $63.7M | $63.7M | $63.7M | $63.7M |
| Operating Leases | $234.8M | $233.2M | $172.6M | $159.0M |
| LT Securities | — | — | $637.3M | $603.6M |
| LT Investments | $756.7M | $728.7M | — | — |
| Other LT Assets | $286.9M | $470.0M | $487.2M | $475.9M |
| Total Assets | $3.07B | $2.94B | $2.95B | $2.84B |
| Current Liabilities | $324.4M | $394.3M | $403.8M | $405.6M |
| Accounts Payable | $32.7M | $33.8M | $38.2M | $29.6M |
| Current Leases | $17.7M | $25.7M | $25.0M | $27.9M |
| Deferred Revenue | $7.5M | $5.4M | $2.7M | $1.1M |
| Other Current Liab | $266.5M | $329.4M | $337.8M | $347.0M |
| Long-Term Liabilities | $258.7M | $284.2M | $299.7M | $277.5M |
| LT Operating Leases | $190.2M | $189.9M | $190.8M | $173.0M |
| Other LT Liab | $62.0M | $88.7M | $105.5M | $98.3M |
| Total Liabilities | $583.1M | $678.4M | $703.5M | $683.1M |
| Shareholders' Equity | $2.49B | $2.26B | $2.24B | $2.16B |
| Paid-In Capital | $2.54B | $2.44B | $2.34B | $2.23B |
| Retained Earnings | $-34.2M | $-173.4M | $-98.6M | $-76.8M |
| AOCI | $-14.5M | $-3.8M | $-1.3M | $3.5M |
| Total L&E | $3.07B | $2.94B | $2.95B | $2.84B |
| Metric | 2022 | 2023 | 2025 | 2026 |
|---|---|---|---|---|
| Net Income (CFO) | $182.3M | $207.8M | $521.3M | $782.6M |
| Non-Cash Adjustments | $186.6M | $-124.5M | $149.9M | $133.2M |
| Working Capital Changes | $-6.3M | $250.1M | $28.8M | $-31.5M |
| Cash from Operations | $362.6M | $333.3M | $700.0M | $884.3M |
| Capital Expenditures | $27.7M | $40.5M | $28.4M | $8.4M |
| Cash from Investing | $-524.4M | $-27.0M | $-116.8M | $350.4M |
| Share Buybacks | — | $550.4M | $652.0M | $947.5M |
| Cash from Financing | $586.0K | $-546.1M | $-628.8M | $-969.6M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-161.2M | $-239.7M | $-45.6M | $265.1M |
| Beginning Cash | $663.9M | $502.7M | $263.0M | $217.4M |
| Ending Cash | $502.7M | $263.0M | $217.4M | $482.5M |
Frequently Asked Questions
How does EXELIXIS, INC. make money?
The company's revenue is primarily derived from the sale of its proprietary oncology drugs, including Exondys 51 for Duchenne muscular dystrophy and other cancer therapeutics. A significant portion of expenses is allocated to research and development, specifically targeting genetic mutations in cancer patients, while general and administrative costs support global commercialization efforts. The balance sheet reflects substantial investments in long-term marketable securities to fund future drug development pipelines.
What are the main risks for EXEL?
The biopharmaceutical industry faces high regulatory risk, as approval delays or rejections from the FDA could significantly impact revenue projections for upcoming drug candidates. Intense competition from large pharmaceutical incumbents and other biotech firms in oncology may erode market share and pricing power for Exelixis's products. Dependence on a limited number of key products exposes the company to product-specific risks, including potential patent expirations or loss of exclusivity.
What is EXEL's competitive advantage?
Exelixis possesses a differentiated proprietary platform capable of identifying and developing targeted therapies for specific genetic mutations not addressed by standard-of-care treatments. The company maintains a strong cash position with over $482 million in cash and equivalents, providing ample runway to commercialize its pipeline without immediate need for capital raises. Its focus on rare diseases and oncology creates high barriers to entry through complex scientific data and specialized clinical trial expertise.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.